The Motley Fool EN

Why Bristol Myers Squibb Stock Crushed it in February

It delivered for shareholders in its fourth quarter of 2025 with a double beat on analyst projections.

Mar 08, 2026 &03470808202631; 23:47 UTC www.fool.com Trending 3/5

Read original on www.fool.com ↗

↗

Positive for markets

Sentiment score: +75/100

Moderate impact Short-term (days)

WHAT THIS MEANS

Bristol Myers Squibb delivered strong fourth quarter 2025 results, beating analyst expectations on both earnings and revenue metrics, driving significant shareholder value creation in February. The double beat demonstrates solid operational execution and positive momentum heading into 2026.

AI CONFIDENCE

85% Very high

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↑

BMY

BMYStock

Expected to rise

Strong Q4 2025 earnings beat on both EPS and revenue; positive guidance signals and operational momentum

↑

S&P 500

^GSPCIndex

Expected to rise

Healthcare/pharma sector strength from major cap pharmaceutical company outperformance

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Consider accumulating BMY on any pullbacks given the positive earnings surprise and momentum. Monitor for guidance updates and pipeline progress announcements that could sustain the bullish trend in the near term.

KEY SIGNALS

Double beat on Q4 2025 earnings and revenueStrong shareholder value creationPositive earnings momentumPotential upside guidance revision

SECTORS INVOLVED

HealthcarePharmaceuticalsBiotechnology

Analysis generated on Mar 09, 2026 at 15:26 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by The Motley Fool. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Why Bristol Myers Squibb Stock Crushed it in February

RELATED INTELLIGENCE